Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Cell Rep ; 23(2): 349-360, 2018 Apr 10.
Artigo em Inglês | MEDLINE | ID: mdl-29641996

RESUMO

Transcriptional dysregulation of the MYC oncogene is among the most frequent events in aggressive tumor cells, and this is generally accomplished by acquisition of a super-enhancer somewhere within the 2.8 Mb TAD where MYC resides. We find that these diverse cancer-specific super-enhancers, differing in size and location, interact with the MYC gene through a common and conserved CTCF binding site located 2 kb upstream of the MYC promoter. Genetic perturbation of this enhancer-docking site in tumor cells reduces CTCF binding, super-enhancer interaction, MYC gene expression, and cell proliferation. CTCF binding is highly sensitive to DNA methylation, and this enhancer-docking site, which is hypomethylated in diverse cancers, can be inactivated through epigenetic editing with dCas9-DNMT. Similar enhancer-docking sites occur at other genes, including genes with prominent roles in multiple cancers, suggesting a mechanism by which tumor cell oncogenes can generally hijack enhancers. These results provide insights into mechanisms that allow a single target gene to be regulated by diverse enhancer elements in different cell types.


Assuntos
Elementos Facilitadores Genéticos , Proteínas Proto-Oncogênicas c-myc/metabolismo , Motivos de Aminoácidos , Sítios de Ligação , Fator de Ligação a CCCTC/metabolismo , Sistemas CRISPR-Cas/genética , Linhagem Celular Tumoral , Proliferação de Células , Metilação de DNA , Edição de Genes , Regulação Neoplásica da Expressão Gênica , Humanos , Regiões Promotoras Genéticas , Ligação Proteica , Proteínas Proto-Oncogênicas c-myc/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA